DDInter1082 DDInter495
Lixisenatide is a glucagon-like peptide-1 (GLP-1) receptor agonist used in the treatment of type II diabetes mellitus (T2DM). It is sold by Sanofi-Aventis under the brand name Adlyxin in the US and Lyxumia in the EU. Adlyxin recieved FDA approval July 28, 2016.
Delafloxacin is a fluoroquinolone antibiotic which has been used in trials studying the treatment and basic science of Gonorrhea, Hepatic Impairment, Bacterial Skin Diseases, Skin Structure Infections, and Community Acquired Pneumonia, among others. It was approved in June 2017 under the trade name Baxdela for use in the treatment of acute bacterial skin and skin structure infections.
Delafloxacin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Altretamine
Delafloxacin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Calcium glubionate anhydrous
Delafloxacin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Magnesium oxide
Delafloxacin {u} may lead to a major life threatening interaction when taken with {v} Tolbutamide
Delafloxacin may cause a minor interaction that can limit clinical effects when taken with Altretamine
Delafloxacin may cause a moderate interaction that could exacerbate diseases when taken with Calcium glubionate anhydrous
Delafloxacin may cause a moderate interaction that could exacerbate diseases when taken with Magnesium oxide
Delafloxacin may lead to a major life threatening interaction when taken with Tolbutamide